Kelly Paul Edward 4
4 · RELMADA THERAPEUTICS, INC. · Filed May 29, 2024
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2024-05-24+43,700→ 109,372 totalExercise: $2.48From: 2024-03-15Exp: 2033-12-15→ Common Stock (43,700 underlying) - Other
Stock Option (right to buy)
2024-05-24−43,700→ 65,672 totalExercise: $2.48From: 2024-03-15Exp: 2033-12-15→ Common Stock (43,700 underlying)
Footnotes (2)
- [F1]On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 43,700 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares.
- [F2]On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.